Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study.

Autor:	Mrak D; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Simader E; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Sieghart D; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Mandl P; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Radner H; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Perkmann T; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria., Haslacher H; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria., Mayer M; Center for Virology, Medical University of Vienna, Vienna, Austria., Koblischke M; Center for Virology, Medical University of Vienna, Vienna, Austria., Hofer P; Department of Pathology, Medical University of Vienna, Vienna, Austria., Göschl L; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Kartnig F; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Deimel T; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Kerschbaumer A; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Hummel T; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.; 2nd Department of Medicine, Lower Austrian Competence Center for Rheumatology, Landesklinikum Stockerau, Stockerau, Lower Austria, Austria., Kornek B; Department of Neurology, Medical University of Vienna, Vienna, Austria., Thalhammer R; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria., Stiasny K; Center for Virology, Medical University of Vienna, Vienna, Austria., Winkler S; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria., Smolen JS; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Aberle JH; Center for Virology, Medical University of Vienna, Vienna, Austria., Aletaha D; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Heinz LX; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Bonelli M; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria michael.bonelli@meduniwien.ac.at.
Jazyk:	angličtina
Zdroj:	Annals of the rheumatic diseases [Ann Rheum Dis] 2022 Dec; Vol. 81 (12), pp. 1750-1756. Date of Electronic Publication: 2022 Aug 17.
DOI:	10.1136/ard-2022-222579
Abstrakt:	Objectives: Patients under rituximab therapy are at high risk for a severe COVID-19 disease course. Humoral immune responses to SARS-CoV-2 vaccination are vastly diminished in B-cell-depleted patients, even after a third vaccine dose. However, it remains unclear whether these patients benefit from a fourth vaccination and whether continued rituximab therapy affects antibody development. Methods: In this open-label extension trial, 37 rituximab-treated patients who received a third dose with either a vector or mRNA-based vaccine were vaccinated a fourth time with an mRNA-based vaccine (mRNA-1273 or BNT162b2). Key endpoints included the humoral and cellular immune response as well as safety after a fourth vaccination. Results: The number of patients who seroconverted increased from 12/36 (33%) to 21/36 (58%) following the fourth COVID-19 vaccination. In patients with detectable antibodies to the spike protein's receptor-binding domain (median: 8.0 binding antibody units (BAU)/mL (quartiles: 0.4; 13.8)), elevated levels were observed after the fourth vaccination (134.0 BAU/mL (quartiles: 25.5; 1026.0)). Seroconversion and antibody increase were strongly diminished in patients who received rituximab treatment between the third and the fourth vaccination. The cellular immune response declined 12 weeks after the third vaccination, but could only be slightly enhanced by a fourth vaccination. No unexpected safety signals were detected, one serious adverse event not related to vaccination occurred. Conclusions: A fourth vaccine dose is immunogenic in a fraction of rituximab-treated patients. Continuation of rituximab treatment reduced humoral immune response, suggesting that rituximab affects a second booster vaccination. It might therefore be considered to postpone rituximab treatment in clinically stable patients. Trial Registration Number: 2021-002348-57. Competing Interests: Competing interests: PM reports speaker fees from AbbVie, Janssen and Novartis and research grants from AbbVie, BMS, Novartis, Janssen, MSD and UCB. MB reports about personal fees from Eli-Lilly, DA received grants and consulting fees from AbbVie, Amgen, Lilly, Merck, Novartis, Pfizer, Roche and Sandoz. JSS reports about grants, consulting and personal fees from AbbVie, Astra-Zeneca, Lilly, Novartis, Amgen, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche, Samsung and UCB. DM received support for meeting attendances from Pfizer. HH received grants from Glock Health, BlueSky Immunotherapies and Neutrolis. AK reports about speaker and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, Merck Sharp and Dohme, Novartis and Pfizer. All other authors declare no competing interests. (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu